Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Risks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy.|
|Authors: ||Bos, Wendy|
Westra, Anna E.
Mayer, Matthew P.
Lantos, John D.
|Issue Date: ||2015|
|Citation: ||PEDIATRICS, 136 (6), p. 1173-1177|
|Abstract: ||Studies of innovative therapies for muscular dystrophy raise unique ethical issues. The disease is currently untreatable and relentlessly progressive. A number of potentially efficacious treatments are being developed, but like all treatments, they may have unforeseen adverse effects. Nevertheless, patients and families, facing a bleak future, may be willing to take the gamble and try the treatments. Many doctors are eager to study them. But should institutional review boards approve them? This article discusses these issues and recounts the ways that one such study elicited different responses from different institutional review boards.|
|Notes: ||Lantos, JD (reprint author), Childrens Mercy Hosp, 2401 Gillham Rd, Kansas City, MO 64105 USA.
|ISI #: ||000370254400050|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2017|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.